



Endocrinology and Metabolism
Research Institute



Cyprus Institute of Neurology and
Genetics

Memorandum of Understanding

Between the Cyprus Institute of Neurology and Genetics (CING) in Cyprus
and the Endocrinology and Metabolism Research Institute (EMRI) in the
Islamic Republic of Iran

On Cooperation in the provision of Services, Research and Education in the
fields of Genomics, Proteomics and Metabolomics

The Cyprus Institute of Neurology and Genetics (CING) in Cyprus and the
Endocrinology and Metabolism Research Institute (EMRI) in the Islamic
Republic of Iran (hereinafter referred as "The Parties"),

Wishing to contribute to the development of bilateral relations,

Aware of the significant importance of cooperation and coordination of the
efforts of institutions which are responsible for the provision of Services,
Research and Education in the fields of Genomics, Proteomics and
Metabolomics

REITERATING the desire of strengthening cooperation in exchange of
information and knowledge between the two Institutes in the provision of
Services, Research and Education in the fields of "Omics" studies such as
Genomics, Proteomics and Metabolomics for the purpose of establishing a
long-term mutually beneficial association;

HAVE reached the following understanding:

ARTICLE – 1 (Scope of Cooperation)

The Parties hereby confirm their intention to establish cooperative relationship
for promotion of the above Technology in areas of "Omics" studies such as
Genomics, Proteomics and Metabolomics where experience is available with
the scientists and specialists of the two Institutes for the purpose of
establishing a long-term association in accordance with the relevant laws and

regulations of each country and the terms of this MOU on the basis of equality reciprocity and mutual benefit.


ARTICLE – 2
(Joint Working Group)

1. A CING-EMRI Joint Working Group for Technological Cooperation (hereinafter referred to as the "Working Group") comprising members from the two Institutes shall be established. The Working Group shall consist of one senior person (co-chairperson) and one coordinator from each side. Other members representing scientific agencies/ organizations may be permitted by the Parties to participate as and when necessary.
2. The Working Group shall be responsible for implementing the scope of cooperation as set out in Article 1 of this Memorandum. The Working Group shall be responsible for the following, which inter-alia include:
 - a) Determining the areas of mutual interest and fields of cooperation;
 - b) Exchanging opinions on the overall perspectives of the bilateral scientific and technical cooperation;
 - c) Consideration of new proposals for the development of the cooperation;
 - d) Approving the implementation of joint activities;
 - e) Monitoring and review of the on-going activities;
3. The meetings of the Working Group shall take place annually, or as and when required by mutual agreement, alternately in the Republic of Cyprus and the Islamic Republic of Iran.
4. Key deliverables for the Working Group would be identified and agreed by the Parties before each meeting of the Working Group.

ARTICLE – 3
(Areas of Joint Cooperation)

The areas of mutual interest for developing and implementing cooperation programmes under this MOU fall under the fields of "Omics" studies such as Genomics, Proteomics and Metabolomics.

ARTICLE – 4
(Modes of Cooperation)




The following modes of collaboration have been agreed upon:

1.
 - a. Facilitate interdisciplinary studies and intellectual interactions, training, sharing of facilities for high-throughput genomic, proteomic and metabolomics studies, and the acquisition of resources and grants;
 - b. Promote interdisciplinary research and education in a rapidly growing area of biological research;
 - c. Facilitate research by supporting technology platforms for DNA sequencing and typing, gene expression studies, protein and metabolite interaction studies, and bioinformatics analyses;
 - d. Develop knowledge and other infrastructures in the field of "omics" studies;
 - e. Perform various international basic and clinical projects;
 - f. Translate basic sciences finding to the clinic;
 - g. Exchange of scientists, specialists, students and trainees;
 - h. Implementation of joint technical research projects and application of the results of such joint research in the above areas;
 - i. Joint scientific and technical workshops, conferences, training programmes, seminars and courses on identified themes in the fields of "Omics" studies such as Genomics, Proteomics and Metabolomics;
 - j. Exchange of scientific & technical information and documentation;
 - k. Development of strategies for achievement of the objectives of this MOU; and other forms of cooperation which may mutually be considered suitable by the Parties.
2. The Parties shall support Joint Projects in the areas of mutual interest which shall be developed jointly by the EMRI and the CING.

ARTICLE – 5
(Terms of Cooperation)

1. All Cooperative activities under this MOU will be conducted:
 - a) On the basis of mutual respect of each party's autonomy
 - b) In conformity with the laws and regulations in force in each country



- c) Subject to the availability of funds and other resources of the Parties, taking into account their priorities.
2. The Parties will coordinate their actions and make effort, individually and cooperatively, to secure the financial resources necessary to maintain a substantive Cooperation.
3. In accordance with the principle of mutual and equal benefit, the cost of all cooperative activities under this MOU will be shared by the Parties in a manner to be mutually agreed upon.
4. The Parties will facilitate the entry to, stay in, and exit from the host country for the participants in the programmes of cooperation within the framework of this MOU.
5. Other entities in Cyprus and the Islamic Republic of Iran may, if they so decide, sign protocols on the practical implementation of specific joint activities under this MOU with the prior approval of the Parties.

ARTICLE – 6
(Release of Information)

The Parties agree not to divulge information obtained by either Party under this MOU to any third party without the written consent of the other Party.

ARTICLE – 7
(Amendments)

This Memorandum of Understanding may be modified or amended as may be required from time to time by mutual written consent of the Parties.

ARTICLE – 8
(Disputes Settlement)

Any and all disputes between the Parties concerning the Memorandum of Understanding shall be settled amicably through consultations and/or negotiations between the Parties.

ARTICLE – 9
(Validity)

1. This Memorandum of Understanding becomes effective on the date of its signature by the authorized representatives of both Parties and will remain in force, unless terminated by either Party by giving three (3) months prior notice in writing to the other Party.



2. The termination of this Memorandum of Understanding will not affect co-operative activities, which are already in progress.

IN WITNESS WHEREOF, the undersigned, being duly authorized here of by their respective organisations, have signed this Memorandum of Understanding at **Ministry of Health and Medical Education, Tehran, Iran** on **6th December 2016** in two originals in the English language, both of which being equally authentic.


Prof. Leonidas A. Phylactou
Chief Executive Medical Director
Cyprus Institute of Neurology and Genetics

For and on behalf of the Cyprus
Institute of Neurology & Genetics, Cyprus


Bagher Larijani

For and on behalf of the
Endocrinology and Metabolism
Research Institute, the Islamic
Republic of Iran

